Abdominal Pain News and Research

RSS

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

FDA approves Ironwood’s LINZESS to treat irritable bowel syndrome with constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced today that LINZESS (linaclotide) was approved by the U.S. Food and Drug Administration (FDA) as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

31 Aug 2012

Ironwood receives FDA approval for Linzess to treat chronic idiopathic constipation, IBS

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

31 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Children with obesity face increased risk for gallstones

Children who are overweight or obese face an increased risk for gallstones, according to a Kaiser Permanente study published in the Journal of Pediatric Gastroenterology & Nutrition.

26 Aug 2012

Clinical trial to test whether fecal transplantation is effective in treating relapsing C. difficile

For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.

22 Aug 2012

Abdominal pain duration influences appendicitis imaging diagnosis

Clinicians should not rely on ultrasonography for diagnosing pediatric appendicitis early in the course of illness, say US researchers.

14 Aug 2012

Combination therapy does not change safety and efficacy relationship of TORISEL for advanced RCC

Pfizer Inc. announced that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-α-2a) in the first-line treatment of patients with advanced renal cell carcinoma (RCC) across risk groups, did not meet its primary endpoint of superiority in extending progression free survival (PFS) in the study population.

12 Aug 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

8 Aug 2012

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

New York University College of Nursing's (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, LAc., the Independence Foundation Endowed Professor and Founding Director of the Division of Special Studies in Symptom Management at NYUCN has been awarded a $2.5 million four-year National Institutes of Health (NIH) grant for the study of "Symptom management for irritable bowel syndrome (IBS) constipation".

7 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

21 Jul 2012

EMA accepts Pfizer’s bazedoxifene/conjugated estrogens MAA for review

Pfizer Inc. today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.

19 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012